MOR MorphoSys AG

-0.29  -1%
Previous Close 22.94
Open 22.83
Price To Book 5.15
Market Cap 2859203362
Shares 126,234,144
Volume 11,788
Short Ratio
Av. Daily Volume 31,493

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b released October 21, 2018 did not meet primary endpoint.
Rheumatoid Arthritis
Phase 2 data due 2H 2019.
Atopic dermatitis
Pivotal trial to be initiated 2019.
Multiple Myeloma (MM)
Phase 2 data to be presented in 2019.
MOR208 + idelalisib (COSMOS)
Chronic Lymphocytic Leukemia
Phase 3 interim analysis 2H 2019.
Bendamustine + MOR208 - B-MIND
Relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL)
Phase 2 top-line data due mid-2019.
Lenalidomide + MOR208 - L-MIND
Relapsed or refractory diffuse large B cell lymphoma
Phase 3 enrollment has commenced - noted June 14, 2018.
Early Alzheimer's disease
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 2 trial initiation announced November 19, 2018.
Guselkumab (NOVA)
Hidradenitis Suppurativa
Phase 3 primary endpoint met - December 12, 2019.
Guselkumab vs Cosentyx - ECLIPSE
Phase 2a initiation announced January 17, 2019.
Ulcerative colitis
Approval announced February 27, 2019.
Plaque psoriasis
Phase 1b trial to be initiated 2H 2019.
Front-line diffuse large B cell lymphoma (DLBCL)

Latest News

  1. MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma
  2. MorphoSys Presents Results for Fiscal Year 2018
  3. MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL
  4. Invitation to Year-End Results 2018 Conference Call of MorphoSys AG on March 14, 2019
  5. MorphoSys to Present at Upcoming Investor Conference
  6. Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire
  7. Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire
  8. MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab
  9. MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
  10. The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug
  11. MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis
  12. MorphoSys AG: Corporate Calendar 2019
  13. MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
  14. MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018
  15. MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis
  16. The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings
  17. MorphoSys to Present at Upcoming Investor Conferences
  18. The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings
  19. MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa